Suboxone Monopoly Suit Settled by Indivior

Indivior, the manufacturer of the opioid addiction drug Suboxone, has settled with more than 40 states and Washington D.C. over claims that the company has unfairly extended its monopoly on the life-saving drug, according to Consumer Notice. According to the lawsuit, Indivior undertook a series of actions that ensured that the company could maintain a monopoly of their drug Suboxone. Buprenorphine, known by its commercial name Suboxone, is an opioid agonist used in the treatment of individuals with opioid use disorder. An opioid agonist works to activate the opioid receptors of the brain, resulting in a reduction of withdrawal symptoms in patients recovering from opioid use disorder. Suboxone in particular is seen as a more long-term solution than its alternative naltrexone while being just as effective as methadone. <a href="https://medtruth.medium.com/suboxone-monopoly-suit-settled-by-indivior-680615688f43">Read More</a>